ALK y ROS-1 en CNMP: Presente y Futuro - page 23

LORLATINIB

Gainor E, et al. Cancer Discov 2016

Felip E, et al. WCLC 2016

Phase I

N=41 pts

ORR=46%

mPFS=9,6 m

Distinc Toxicity!

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,13,14,15,16,17,18,19,20,21,22 24,25,26,27,28,29,30,31,32,...33